Targazyme Presents TZ-102 Cancer Immunotherapy Preclinical Results at the World Orphan Drug Congress – GlobeNewswire (press release)
|
Targazyme Presents TZ-102 Cancer Immunotherapy Preclinical Results at the World Orphan Drug Congress
GlobeNewswire (press release) CARLSBAD, Calif., April 26, 2018 (GLOBE NEWSWIRE) — Targazyme, Inc. a late clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy outcomes for cancer immunotherapy and stem cell … |
